Eclampsia and HELLP Syndrome: Emergency Management

Pregnancy-specific emergencies are among the most time-critical situations in emergency medicine – and they always involve two patients simultaneously. Eclampsia and HELLP syndrome present particular challenges: the clinical presentation can be atypical, the differential diagnosis is broad, and the therapeutic window is narrow. If you are confronted with these conditions as an emergency physician, anesthesiologist, or nurse in acute care, you must have a solid command of the algorithms while also considering the obstetric perspective. This article summarizes the evidence-based emergency management of eclampsia and HELLP syndrome – from initial assessment to pharmacological therapy and delivery indications.

Pathophysiological Fundamentals

Eclampsia and HELLP syndrome are manifestations of a spectrum of hypertensive disorders of pregnancy, whose common origin is impaired placentation with consecutive endothelial dysfunction. Inadequate trophoblast invasion of the spiral arteries leads to placental hypoperfusion. The resulting systemic endothelial activation explains the multi-organ involvement: vasospasm, increased vascular permeability, platelet activation, and coagulation disorders.

Eclampsia

Eclampsia is defined as the occurrence of generalized tonic-clonic seizures in a pregnant woman with preeclampsia that cannot be explained by other causes (epilepsy, cerebral hemorrhage, infection). Important: Up to 20% of eclamptic seizures occur without prior severe hypertension or proteinuria. Eclampsia can occur antepartum, intrapartum, or up to 6 weeks postpartum.

HELLP Syndrome

The acronym describes the triad:

• Hemolysis – microangiopathic hemolytic anemia
• Elevated Liver enzymes – elevated liver enzymes (AST, ALT, LDH)
• Low Platelets – thrombocytopenia (< 100,000/µl)

HELLP syndrome can occur as a severe form of preeclampsia but manifests in up to 15–20% of cases without prior hypertension or proteinuria. These atypical presentations make the diagnosis particularly challenging.

Clinical Recognition and Differential Diagnosis

Reliable recognition of both conditions begins with a high degree of clinical suspicion – especially in any pregnant woman beyond 20 weeks of gestation with unclear symptoms.

Warning Signs of Eclampsia

• Severe hypertension (systolic ≥ 160 mmHg and/or diastolic ≥ 110 mmHg)
• Severe headache unresponsive to analgesics
• Visual disturbances (flickering, scotomas, decreased visual acuity)
• Epigastric or right upper quadrant pain
• Hyperreflexia with clonus
• Nausea, vomiting
• Altered mental status, confusion

Clinical Signs of HELLP Syndrome

• Right upper quadrant or epigastric pain (in up to 90% of cases)
• Nausea and vomiting
• General malaise, "flu-like" symptoms
• Jaundice (in advanced cases)
• Edema, weight gain
• Petechiae, mucosal bleeding (in severe thrombocytopenia)

Important Differential Diagnoses

The symptom overlap with other conditions is substantial and requires a structured diagnostic approach:

Differential Diagnosis	Differentiation
Thrombotic thrombocytopenic purpura (TTP)	ADAMTS13 activity < 10%, neurological symptoms predominant
Hemolytic uremic syndrome (HUS)	Renal involvement in the foreground, often postpartum
Acute fatty liver of pregnancy (AFLP)	Hypoglycemia, prolonged aPTT, hypofibrinogenemia, often jaundice
Epileptic seizure	History, EEG changes, no association with hypertension
Cerebral sinus/venous thrombosis	Imaging (CT/MR venography), focal neurology
Viral hepatitis	Serology, isolated transaminase elevation without hemolysis

Key point: In any pregnant woman with upper abdominal pain, nausea, or elevated transaminases, HELLP syndrome and acute fatty liver of pregnancy must be actively ruled out – even without hypertension.

Diagnostics in the Emergency Setting

You should immediately order the following laboratory values:

• Complete blood count with platelets and blood smear (schistocytes?)
• Hemolysis parameters: LDH, haptoglobin, indirect bilirubin
• Liver enzymes: AST, ALT
• Renal function: creatinine, uric acid
• Coagulation: PT/INR, aPTT, fibrinogen, D-dimers
• Urinalysis: protein-to-creatinine ratio or dipstick
• Blood glucose (to rule out AFLP-associated hypoglycemia)

The Mississippi classification of HELLP syndrome distinguishes three severity grades based on platelet count:

• Class 1: Platelets ≤ 50,000/µl (highest risk)
• Class 2: Platelets 50,000–100,000/µl
• Class 3: Platelets 100,000–150,000/µl

Emergency Management of Eclampsia

The eclamptic seizure is a life-threatening emergency with a maternal mortality of 1–3% and a perinatal mortality of up to 10%. Management follows a clear algorithm.

Immediate Measures During an Eclamptic Seizure

1. Secure the patient: Protect from injury, recovery position, prevent aspiration
2. Airway management: Oxygen administration (15 L/min via mask), suction on standby, intubation readiness
3. Monitoring: SpO₂, ECG, blood pressure measurement, CTG (once patient is stabilized)
4. Magnesium sulfate as first-line therapy – NO benzodiazepine as first-line anticonvulsant

Magnesium Sulfate Protocol

Magnesium sulfate (MgSO₄) is the treatment of choice for seizure control and seizure prevention in eclampsia and severe preeclampsia. This is robustly supported by the landmark Magpie Trial and the Eclampsia Trial Collaborative Group and is recommended by all relevant guidelines.

Loading Dose:

• 4–6 g MgSO₄ IV over 15–20 minutes (typically 4 g as the standard dose, repeat with 2 g if needed)

Maintenance Dose:

• 1–2 g/h IV as continuous infusion (typically 1 g/h)
• Continue for at least 24 hours after the last seizure or after delivery

Therapeutic Level:

• Target range: 4–8 mg/dL (2–4 mmol/L)

Monitoring During Magnesium Therapy:

• Patellar tendon reflex (PTR): must remain elicitable – loss of PTR is the first clinical sign of overdose
• Respiratory rate: > 12/min
• Urine output: > 25 mL/h (> 100 mL in 4 hours)
• SpO₂ monitoring

In Case of Magnesium Toxicity (loss of reflexes, respiratory depression, bradycardia):

• Immediately stop the infusion
• Calcium gluconate 10%: 10 mL (= 1 g) slow IV over 3 minutes as antidote
• Secure airway if needed

In Case of Refractory Seizure (despite adequate magnesium administration):

• Additional 2 g MgSO₄ IV bolus
• If seizure activity persists: benzodiazepines (diazepam 5–10 mg IV or midazolam 1–2 mg IV)
• As last resort: thiopental, propofol, or intubation with induction of general anesthesia

Blood Pressure Management

Severe hypertension (≥ 160/110 mmHg) must be treated promptly – it is an independent risk factor for cerebral hemorrhage, the most common cause of death in eclampsia.

Target blood pressure: 140–150/90–100 mmHg – NO excessively rapid or aggressive reduction (risk of placental hypoperfusion).

Pharmacological Options for Acute Therapy:

Medication	Dosing	Considerations
Urapidil (Ebrantil)	6.25–12.5 mg IV bolus, repeat if needed; infusion 2–8 mg/h	First-line agent in German-speaking countries
Labetalol	20 mg IV initially, escalate to 40–80 mg every 10 min (max. 300 mg)	Internationally preferred first-line medication
Nifedipine (oral)	10 mg PO, repeat after 20–30 min if needed	Only if swallowing ability is preserved; caution: not sublingual
Dihydralazine	5 mg IV slowly, repeat if needed	Increasingly rarely used due to side effect profile

Caution: ACE inhibitors, angiotensin II receptor blockers, and sodium nitroprusside are contraindicated in pregnancy.

Emergency Management of HELLP Syndrome

HELLP syndrome can progress within hours from a mild laboratory constellation to life-threatening multi-organ dysfunction. The most feared complications are:

• Liver rupture / subcapsular liver hematoma
• Disseminated intravascular coagulation (DIC)
• Placental abruption (in up to 16% of cases)
• Acute renal failure
• Pulmonary edema
• Cerebral hemorrhage

Therapeutic Algorithm

1. Stabilization: Intravenous access (large-bore), draw crossmatch samples, prepare blood products
2. Magnesium sulfate: As with eclampsia – seizure prophylaxis in all patients with HELLP syndrome (seizure risk is elevated)
3. Blood pressure control: As described above for values ≥ 160/110 mmHg
4. Coagulation management:
   • Platelet concentrates for active bleeding and platelets < 20,000/µl
   • Before operative delivery: aim for platelet substitution at values < 50,000/µl
   • FFP for pathological coagulation with signs of bleeding
5. Laboratory monitoring: Every 6 hours (platelets, transaminases, LDH, coagulation)
6. Imaging: Upper abdominal ultrasound to rule out subcapsular liver hematoma in cases of severe upper abdominal pain

Corticosteroids in HELLP Syndrome

The use of high-dose corticosteroids (dexamethasone 10 mg IV every 12 h) to improve maternal laboratory parameters in HELLP syndrome is controversially discussed. According to current evidence, corticosteroids lead to a faster recovery of platelet counts; however, an improvement in maternal outcomes has not been clearly demonstrated. Fetal lung maturation with betamethasone (2 × 12 mg IM 24 hours apart) or dexamethasone (4 × 6 mg IM 12 hours apart) is indicated for preterm delivery between 24 and 34 weeks of gestation.

Delivery Indications and Timing

Delivery is the only causal therapy for eclampsia and HELLP syndrome. The central question is timing – weighing maternal risks against fetal maturity.

Immediate Delivery (within hours)

• Eclampsia (after maternal stabilization)
• HELLP syndrome ≥ 34+0 weeks of gestation
• HELLP syndrome < 34 weeks of gestation with:
  • Refractory severe hypertension
  • DIC
  • Liver rupture/subcapsular hematoma
  • Acute renal failure
  • Placental abruption
  • Pathological CTG
  • Pulmonary edema

Expectant Management (under intensive monitoring)

• HELLP syndrome < 34 weeks of gestation without maternal complications: stabilization and lung maturation over 48 hours may be considered – however, only in a perinatal center with the highest level of care
• Frequent laboratory monitoring and CTG surveillance are mandatory
• In case of deterioration: immediate delivery

Mode of Delivery

Eclampsia or HELLP syndrome per se are not mandatory indications for cesarean section. The decision depends on:

• Gestational age and cervical ripeness
• Fetal condition
• Severity of maternal disease
• Coagulation status (caution: regional anesthesia is generally contraindicated with platelets < 75,000–80,000/µl)

In cases of severe thrombocytopenia requiring general anesthesia, airway management should be performed by experienced anesthesiologists – intubation in pregnant patients carries inherently increased risk (mucosal edema, difficult airway, aspiration risk).

Postpartum Management

Both conditions can worsen postpartum or manifest for the first time. Up to 30% of HELLP syndromes occur postpartum.

• Magnesium sulfate: Continue for at least 24 (up to 48) hours postpartum
• Blood pressure monitoring: Closely for at least 72 hours
• Laboratory monitoring: Platelets and transaminases should show a declining trend – the platelet nadir typically occurs 24–48 hours postpartum
• Long-term antihypertensive therapy: Extended-release nifedipine, urapidil, or labetalol; nifedipine and labetalol are preferred in breastfeeding mothers
• Thromboprophylaxis: Individual risk-benefit assessment in the setting of thrombocytopenia

Interprofessional Collaboration and Transport

The management of eclampsia and HELLP syndrome requires close collaboration between emergency medicine, obstetrics, anesthesiology, neonatology, and intensive care. In the prehospital setting, the following priorities apply:

• Primary goal: Maternal stabilization (airway, seizure control, blood pressure)
• Transport: To the nearest perinatal center with neonatology and intensive care unit – not to the nearest hospital
• Pre-notification: Early alerting of the obstetric team, anesthesiology, and neonatology
• Positioning: Left lateral tilt (to prevent aortocaval compression syndrome from approximately 20 weeks of gestation)
• Documentation: Last known blood pressure, seizure duration, medications administered (especially magnesium dose)

Summary of Key Points

• Eclampsia and HELLP syndrome are life-threatening emergencies that can also present atypically and without classic signs of preeclampsia
• Magnesium sulfate is the anticonvulsant of choice – loading dose 4–6 g IV, maintenance 1–2 g/h
• In case of magnesium toxicity: calcium gluconate 10% as antidote
• Severe hypertension ≥ 160/110 mmHg: urapidil or labetalol as first-line therapy, target 140–150/90–100 mmHg
• Delivery is the only causal therapy – timing depends on disease severity and gestational age
• Postpartum monitoring is essential, as deterioration and first manifestations can occur postpartum

Practical Training

Managing eclampsia and HELLP syndrome requires not only theoretical knowledge but also well-practiced workflows under stress – from the reliable magnesium protocol to airway management in the seizing pregnant patient to interdisciplinary communication. In the emergency physician refresher course by Simulation Tirol, you train these time-critical scenarios in realistic simulations and strengthen your decision-making skills for real-life emergencies. Because especially in pregnancy-specific emergencies, every minute counts – for two lives at once.